Endometrial Adenocarcinoma — Trials

Endometrial Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 41
Recruiting: 18
Ph III recruiting: 2
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (12)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02208375	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian	active not recruiting	Phase 1	159	M.D. Anderson Cancer CenterOTHER	1	Sep 4, 2026	clinicaltrials
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	active not recruiting	Phase 1	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials